// App-Quantinova.ai

: Outcomes in patients (Pts) with advanced prostate cancer and inactivating germline mutations in BRCA2 or ATM.

Researchers

Presenter

  • Steven Yip

Principal Investigators

  • Daniel Khalaf

  • Werner J. Struss

  • Katherine Sunderland

  • Gillian Vandekerkhove

  • Evan W Warner

  • Matti Annala

  • Alexander William Wyatt

  • Kim N. Chi

Medical Centers

  • BC Cancer - Vancouver Centre, Vancouver, BC, Canada

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • BC Cancer Agency, Vancouver, BC, Canada

  • Institute of Biosciences and Medical Technology, Tampere, Finland

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Breast cancer type 2 susceptibility protein

  • Hormone receptor

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved